Long-Term Follow-Up of Patients With Idiopathic Pulmonary Fibrosis Treated With Pirfenidone or Nintedanib: A Real-Life Comparison Study

Long-Term Follow-Up of Patients With Idiopathic Pulmonary Fibrosis Treated With Pirfenidone or Nintedanib: A Real-Life Comparison Study

BackgroundPirfenidone and nintedanib are the sole pharmacological therapies currently approved for idiopathic pulmonary fibrosis (IPF). Limited comparison data is available in literature, despite they are both prescribed for mild-to-moderate disease. Here, we describe our almost 10 years real-life e...

Full description

Bibliographic Details
Main Authors: Paolo Cameli, Rosa Metella Refini, Laura Bergantini, Miriana d’Alessandro, Valerio Alonzi, Carlo Magnoni, Paola Rottoli, Piersante Sestini, Elena Bargagli
Format: Article
Language:English
Published: Frontiers Media S.A. 2020-09-01
Series:Frontiers in Molecular Biosciences
Subjects:
idiopathic pulmonary fibrosis
real-life
pirfenidone
nintedanib
disease progression
mortality
Online Access:https://www.frontiersin.org/article/10.3389/fmolb.2020.581828/full

Internet

https://www.frontiersin.org/article/10.3389/fmolb.2020.581828/full

Similar Items